Matthew Feinsod
Chief Medical OfficerDr. Matthew Feinsod, M.D., also known as Matt, is Chief Medical Officer at Kalaris Therapeutics, Inc. since December 2024. Dr. Feinsod served as Executive Vice President of Global Strategy and Development at Applied Genetic Technologies Corporation since August 1, 2019 until 2022. Dr. Feinsod was Interim Chief Medical Officer of Applied Genetic Technologies Corporation since September 5, 2017 until July 29, 2019 and served as its Product Development Office. Dr. Feinsod Co-founded and served as the Chief Medical Officer of Imagen Biotech, Inc. Dr. Feinsod served as Senior Vice President of Strategy & Product Development at Eyetech Pharmaceuticals from 2003 to 2007, where he spent five years in a variety of functions helping to develop and launch Macugen and an anti-PDGF aptamer now in Phase 3 clinical trials with Ophthotech. Prior to joining Eyetech, Dr. Feinsod served as a Medical Officer for the FDA Division of Anti-inflammatory, Analgesic and Ophthalmologic Drug Products from 2002 to 2003, where he was a primary reviewer for both IND and NDA ophthalmology regulatory applications. Concurrently, he held a clinical trials/drug development fellowship position in George Washington University's Department of Ophthalmology and served on the University hospital's Institutional Review Board. Previously, Dr. Feinsod conducted post-doctoral molecular biology research with a focus on nucleotide science at Cornell University Medical Center. He joined AGTC in July 2014 and has played key roles in developing and implementing clinical and regulatory strategy, due diligence and licensing. Dr. Feinsod is a board-certified ophthalmologist with extensive corporate and regulatory expertise in the development of novel therapies for ophthalmic diseases. In his previous positions, he has played key roles in corporate finance, developing and implementing clinical and regulatory strategy, due diligence and licensing. Dr. Feinsod serves on the board of directors of World Eye Mission, a non-profit organization. He continues to practice ophthalmology on a part-time basis. Dr. Feinsod holds several patents in the field of ophthalmology and in emitted light-stabilization. He received his BS from the Wharton School of Business, at the University of Pennsylvania and his MD from the George Washington University School of Medicine and completed his residency at the Manhattan Eye, Ear and Throat Hospital.
Positions
- Company NameKalaris Therapeutics, Inc.Stock CodeKLRSPositionChief Medical Officer
